Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Orexigen Therapeutics, Inc. (OREX)

-NasdaqGS
5.30 Down 0.08(1.49%) Apr 17, 4:00PM EDT
|After Hours : 5.33 Up 0.03 (0.57%) Apr 17, 7:59PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
United States - Map
Phone: 858-875-8600
Fax: 858-875-8650
Website: http://www.orexigen.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:50

Business Summary 

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Orexigen Therapeutics, Inc.

Corporate Governance 
Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 10. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Michael A. Narachi M.S., M.B.A., 55
Chief Exec. Officer, Pres and Director
1.22M2.61M
Mr. Joseph P. Hagan , 45
Acting Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Treasurer
599.00K570.00K
Ms. Heather D. Turner J.D., 41
Sr. VP, Gen. Counsel and Sec.
599.00K496.00K
Mr. Mark D. Booth , 54
Chief Commercial Officer
478.00K413.00K
Dr. Preston S. Klassen M.D., M.H.S., 45
Head of Global Contrave Program and Sr. VP of Product Devel.
610.00K0.00
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders